Corrigendum

This article refers to:

Insulin degludec early clinical experience: does the promise from the clinical trials translate into clinical practice—a case-based evaluation

Correction to: Insulin degludec early clinical experience: does the promise from the clinical trials translate into clinical practice—a case-based evaluation

Marc Evans

Llandough Hospital, Diabetes Resource Centre, Cardiff, UK

Phil McEwan

University of Swansea, Swansea Centre for Health Economics, Swansea, UK

Volker Foos

IMS Health, Health Economics & Outcomes Research, Basel, Switzerland

Since the publication of the above article in Journal of Medical Economics Vol. 18, No. 2, 2015, 96–105 the authors have informed the publishers of an error in Table 1.

Table 1. Baseline demographics of first 51 consecutive patients switching from IDet or IGlar to IDeg in routine clinical practice in the UK.

	T1D (n¼35)	T2D (n¼16)
Gender (M/F)	15/20	9/7
Age (years)	35.0_11.4	62.8_14.7
Diabetes duration (years)	18.2_7.5	16.2_5.0
Previous basal insulin type (IGlar/IDet)	9/26	1/15
Previous basal insulin (units)	27.7_13.3	76.3_37.5
HbA1c	9.4_0.8	9.4_1.1
Episodes of hypoglycemia per week	3.9_0.9	1.0_1.4
Weight (Kg)	77.0_10.7	102.8_23.0

All values are mean_SD, unless otherwise specified.

Previous basal insulin type (IGlar/IDet) should have read:

Previous basal insulin (IDet/IGlar)